Page last updated: 2024-11-05

diaveridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Diaveridine is a synthetic compound that acts as an antagonist of the adenosine A2A receptor. It is used in research to study the role of adenosine signaling in various physiological and pathological processes. Diaveridine has shown potential therapeutic effects in animal models of Parkinson’s disease, Alzheimer's disease, and stroke. The compound has been shown to protect neurons from damage induced by oxidative stress and inflammation. Diaveridine is synthesized through a multi-step chemical process, starting from commercially available starting materials. It is a potent and selective A2A receptor antagonist, with a high affinity for the receptor. Diaveridine is a valuable tool for investigating the role of adenosine signaling in various diseases and for developing novel therapeutic strategies.'

diaveridine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diaveridine : An aminopyrimidine in which the pyrimidine ring carries amino substituents at C-2 and C-4 and a 3,4-dimethoxybenzyl group at C-5. A folic acid antagonist, it is used as a synergist with sulfonamides against the parasitic Eimeria species. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID21453
CHEMBL ID19633
CHEBI ID123115
SCHEMBL ID93896
MeSH IDM0103190

Synonyms (94)

Synonym
AC-12110
brn 0258464
egis 5645
2,4-diamino-5-(3,4-dimethoxybenzyl)pyrimidine
2,4-pyrimidinediamine, 5-((3,4-dimethoxyphenyl)methyl)-
diaveridina [inn-spanish]
diaveridine [usan:inn:ban]
5-((3,4-dimethoxyphenyl)methyl)-2,4-pyrimidinediamine
egis-5645
pyrimidine, 2,4-diamino-5-veratryl-
nsc 408735
diaveridinum [inn-latin]
ccris 3784
einecs 226-333-3
ai3-23935
diaveridine (usan/inn)
D03771
2,4-diamino-5-(3',4'-dimethoxybenzyl)pyrimidine
nsc408735
5-[(3,4-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine
5355-16-8
210u49
bw 49-210
diaveridine
pyrimidine,4-diamino-5-veratryl-
diaveridin
2,4-diamino-5-veratrylpyrimidine
2, 5-[(3,4-dimethoxyphenyl)methyl]-
bw 49210
2,4-dimethoxybenzyl)pyrimidine
nsc-408735
NCGC00160517-01
KUP ,
diaveridina
5-(3,4-dimethoxybenzyl)pyrimidine-2,4-diamine
5-(3,4-dimethoxy-benzyl)-pyrimidine-2,4-diamine
diaveridinum
CHEBI:123115 ,
bdbm50138691
bw-49210
bw-49-210
CHEMBL19633 ,
NCGC00160517-02
HMS3264I16
STK711076
tox21_111866
dtxcid0026200
cas-5355-16-8
dtxsid2046200 ,
A829660
BBL009897
nsc-759634
nsc759634
pharmakon1600-01502300
MLS004712092
smr002529995
AKOS005530708
unii-7kvx81xa87
5-25-13-00391 (beilstein handbook reference)
7kvx81xa87 ,
5-(3,4-dimethoxybenzyl)-2,4-pyrimidinediamine
FT-0603089
EPITOPE ID:119685
diaveridine [usp-rs]
diaveridine [mart.]
diaveridine [usan]
diaveridine [inn]
diaveridine [mi]
S5200
CCG-213021
SCHEMBL93896
NCGC00160517-03
tox21_111866_1
2,4-diamino-5-(3',4'-dimethoxybenzyl) pyrimidine
2,4-diamino-5-(3',4'-dimethoxybenzyl)-pyrimidine
W-105726
2,4-pyrimidinediamine, 5-[(3,4-dimethoxyphenyl)methyl]-
5-(3,4-dimethoxybenzyl)-2,4-pyrimidinediamine #
AB01562957_01
mfcd00057349
Q27212503
ccris-3784
SR-01000939849-2
sr-01000939849
diaveridine, united states pharmacopeia (usp) reference standard
diaveridine, vetranal(tm), analytical standard
diaveridine, analytical standard, >=99.0% (tlc)
diaveridine 10 microg/ml in acetonitrile
CS-0013961
HY-B1902
D81857
AS-56306
EN300-7440332
Z2681892420

Research Excerpts

Overview

Diaveridine (DVD) is a member of the 2,4-pyrimidinediamine class of dihydrofolate reductase inhibitors. It is widely used in combination with sulfonamide.

ExcerptReferenceRelevance
"Diaveridine (DVD) is a popular antibacterial synergist that is widely used in combination with sulfonamide. "( Identification and elucidation of the structure of in vivo metabolites of diaveridine in chicken.
Ding, H; Guo, C; He, L; Huang, X; Kong, X; Wang, H; Wang, W; Yuan, B; Zeng, Z, 2014
)
2.08
"Diaveridine (DVD) is a member of the 2,4-pyrimidinediamine class of dihydrofolate reductase inhibitors. "( Acute, mutagenicity, teratogenicity and subchronic oral toxicity studies of diaveridine in rodents.
Cao, X; Sun, F; Tang, S; Wang, J; Zhang, S, 2015
)
2.09

Toxicity

ExcerptReferenceRelevance
" Thus, our results suggested that the DVD is safe when administered orally in rats at 10mg/kg body weight per day."( Acute, mutagenicity, teratogenicity and subchronic oral toxicity studies of diaveridine in rodents.
Cao, X; Sun, F; Tang, S; Wang, J; Zhang, S, 2015
)
0.65

Compound-Compound Interactions

ExcerptReferenceRelevance
"Trimethoprim (TMP) and diaveridine (DVD) are used in combination with sulfonamides and sulfaquinoxlaine as an effective antibacterial agent and antiprotozoal agent, respectively, in humans and animals."( Characterization of in vitro metabolites of trimethoprim and diaveridine in pig liver microsomes by liquid chromatography combined with hybrid ion trap/time-of-flight mass spectrometry.
Liu, ZY; Sun, ZL; Wan, L; Wu, Y, 2012
)
0.93

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Therefore, the suggested withdrawal period for SPZ-DVD suspension should be 7 days after dosing for seven successive days."( Determination of sulphachloropyrazine-diaveridine residues by high performance liquid chromatography in broiler edible tissues.
Bu, S; Li, Y, 2016
)
0.71
" For 90-day feeding of DVD at the dosage of 10mg/kg body weight in both male and female SD rats, no signs of toxicological effects were detected."( Acute, mutagenicity, teratogenicity and subchronic oral toxicity studies of diaveridine in rodents.
Cao, X; Sun, F; Tang, S; Wang, J; Zhang, S, 2015
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antiparasitic agentA substance used to treat or prevent parasitic infections.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency30.64840.000811.382244.6684AID686978; AID686979
huntingtin isoform 2Homo sapiens (human)Potency31.62280.000618.41981,122.0200AID1688
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseHomo sapiens (human)IC50 (µMol)0.53000.00060.87267.3000AID58106
Dihydrofolate reductaseGallus gallus (chicken)IC50 (µMol)300.00000.00000.12730.4000AID56473
Dihydrofolate reductaseGallus gallus (chicken)Ki34.67370.11220.21580.3311AID56467
Dihydrofolate reductaseLacticaseibacillus caseiKi0.12020.00001.26756.3096AID57779
Dihydrofolate reductaseNeisseria gonorrhoeaeIC50 (µMol)0.53000.45000.49000.5300AID58101; AID58108
Dihydrofolate reductaseEscherichia coli K-12IC50 (µMol)0.07070.00150.55126.8000AID57093; AID57106; AID57591
Dihydrofolate reductaseEscherichia coli K-12Ki0.01910.00000.37904.0200AID57588
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium falciparum K1Ki4.18780.00000.43696.6645AID219251; AID58256; AID58257; AID58258
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium berghei ANKAIC50 (µMol)0.21000.12000.13500.2100AID58112
Dihydrofolate reductase Salmonella enterica subsp. enterica serovar TyphiKi0.01910.00450.11790.6607AID57579
Dihydrofolate reductaseRattus norvegicus (Norway rat)IC50 (µMol)78.00000.00060.35076.2000AID57638; AID57785; AID57788
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interferon gamma precursorHomo sapiens (human)AC5024.53000.128015.173038.6100AID1259418; AID1259420
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseGallus gallus (chicken)
response to methotrexateDihydrofolate reductaseGallus gallus (chicken)
tetrahydrofolate metabolic processDihydrofolate reductaseGallus gallus (chicken)
tetrahydrofolate biosynthetic processDihydrofolate reductaseGallus gallus (chicken)
dihydrofolate metabolic processDihydrofolate reductaseGallus gallus (chicken)
folic acid metabolic processDihydrofolate reductaseGallus gallus (chicken)
10-formyltetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to xenobiotic stimulusDihydrofolate reductaseEscherichia coli K-12
folic acid biosynthetic processDihydrofolate reductaseEscherichia coli K-12
one-carbon metabolic processDihydrofolate reductaseEscherichia coli K-12
response to methotrexateDihydrofolate reductaseEscherichia coli K-12
tetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to antibioticDihydrofolate reductaseEscherichia coli K-12
dihydrofolate metabolic processDihydrofolate reductaseEscherichia coli K-12
folic acid metabolic processDihydrofolate reductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseGallus gallus (chicken)
dihydrofolate reductase activityDihydrofolate reductaseGallus gallus (chicken)
NADP bindingDihydrofolate reductaseGallus gallus (chicken)
dihydrofolate reductase activityDihydrofolate reductaseEscherichia coli K-12
protein bindingDihydrofolate reductaseEscherichia coli K-12
folic acid bindingDihydrofolate reductaseEscherichia coli K-12
oxidoreductase activityDihydrofolate reductaseEscherichia coli K-12
NADP bindingDihydrofolate reductaseEscherichia coli K-12
methotrexate bindingDihydrofolate reductaseEscherichia coli K-12
dihydrofolic acid bindingDihydrofolate reductaseEscherichia coli K-12
NADP+ bindingDihydrofolate reductaseEscherichia coli K-12
NADPH bindingDihydrofolate reductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseGallus gallus (chicken)
cytosolDihydrofolate reductaseEscherichia coli K-12
cytosolDihydrofolate reductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (99)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1404654Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL after 20 hrs by CLSI microdilution assay2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID1404653Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 after 20 hrs by CLSI microdilution assay2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID58257Inhibitory activity against quadruple mutant dihydrofolate reductase (N51I C59R S108N I164L DHFR)2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
AID56785Inhibition of bovine liver Dihydrofolate reductase.1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Inhibition of dihydrofolate reductase: structure-activity correlations of quinazolines based upon molecular shape analysis.
AID57604Binding affinity for dihydrofolate reductase from Lactobacillus casei1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID219252Inhibitory activity against wild-type dihydrofolate reductase (S108N DHFR), relative to trimethoprim2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
AID1404652Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 after 20 hrs by CLSI microdilution assay2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID57638Inhibitory activity against dihydrofolate reductase (DHFR) from rat liver1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 7. Analysis of the effect of 3,5-dialkyl substituent size and shape on binding to four different dihydrofolate reductase enzymes.
AID58279Inhibitory activity against triple mutant dihydrofolate reductase (C59R S108 NI164L DHFR), relative to trimethoprim2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
AID57588Inhibition constant against binding of Escherichia coli dihydrofolate reductase1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules.
AID23497Partition coefficient (logD) (aqueous phase 0.1 N HCl)1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Inhibition of chicken liver dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines. A quantitative structure-activity relationship and graphics analysis.
AID1404650Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 at 5 ug after 18 to 20 hrs by CLSI disk diffusion assay2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID67696In vitro antibacterial activity against Enterobacter aerogenes (2200/86)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID1404657Bactericidal activity against hospital-associated methicillin-resistant Staphylococcus aureus COL preincubated for 20 hrs followed by agar plating and measured after 18 to 20 hrs2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID57591Inhibitory activity against Escherichia coli dihydrofolate reductase at 10e8 M1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 14. 2,3-Dihydro-1-(2,4-diamino-5-pyrimidyl)-1H-indenes as conformationally restricted analogues of trimethoprim.
AID1404656Bactericidal activity against methicillin-resistant Staphylococcus aureus USA300 preincubated for 20 hrs followed by agar plating and measured after 18 to 20 hrs2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID58159The concentration required to inhibit dihydrofolate reductase in rat liver1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
General distance geometry three-dimensional receptor model for diverse dihydrofolate reductase inhibitors.
AID57586Compound is evaluated for the inhibition of dihydrofolate reductase from Escherichia coli1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted-benzyl)-2,4-diaminopyrimidines.
AID58277Inhibitory activity against double mutant dihydrofolate reductase (C59R S108N DHFR), relative to trimethoprim2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
AID57585Inhibitory activity against dihydrofolate reductase (DHFR) from Escherichia coli (expressed as log 1/Kiapp)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Comparison of the inhibition of Escherichia coli and Lactobacillus casei dihydrofolate reductase by 2,4-diamino-5-(substituted-benzyl)pyrimidines: quantitative structure-activity relationships, X-ray crystallography, and computer graphics in structure-act
AID56471Inhibitory activity against chicken dihydrofolate reductase at pH 7.2.1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
A comparison of the inhibitory action of 5-(substituted-benzyl)-2,4-diaminopyrimidines on dihydrofolate reductase from chicken liver with that from bovine liver.
AID1404655Bactericidal activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 preincubated for 20 hrs followed by agar plating and measured after 18 to 20 hrs2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID58258Inhibitory activity against triple mutant dihydrofolate reductase (C59R S108 NI164L DHFR)2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
AID57083Inhibitory activity against dihydrofolate reductase2001Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17
Adaptive neuro-fuzzy inference system: an instant and architecture-free predictor for improved QSAR studies.
AID57579Inhibitory activity against Escherichia coli dihydrofolate reductase1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted-benzyl)pyrimidines with dihydrofolate reductase.
AID1404658Cytotoxicity against human A549 cells after 24 to 48 hrs by fluorescence-based assay2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID57093Inhibitory activity against dihydrofolate reductase (DHFR) from Escherichia coli1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 7. Analysis of the effect of 3,5-dialkyl substituent size and shape on binding to four different dihydrofolate reductase enzymes.
AID201393In vitro antibacterial activity against Salmonella typhi (CN512)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID56467Inhibitory activity against chicken liver dihydrofolate reductase1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
On the structure selectivity problem in drug design. A comparative study of benzylpyrimidine inhibition of vertebrate and bacterial dihydrofolate reductase via molecular graphics and quantitative structure-activity relationships.
AID1404649Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 at 5 ug after 18 to 20 hrs by CLSI disk diffusion assay2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID56461Inhibition of chicken liver dihydrofolate reductase1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Inhibition of chicken liver dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines. A quantitative structure-activity relationship and graphics analysis.
AID57788Inhibitory activity against rat liver dihydrofolate reductase at 10e8 M1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 14. 2,3-Dihydro-1-(2,4-diamino-5-pyrimidyl)-1H-indenes as conformationally restricted analogues of trimethoprim.
AID219251Inhibitory activity against wild-type dihydrofolate reductase (S108N DHFR)2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
AID58108Inhibitory activity against Neisseria gonorrhoeae dihydrofolate reductase at 10e8 M1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 14. 2,3-Dihydro-1-(2,4-diamino-5-pyrimidyl)-1H-indenes as conformationally restricted analogues of trimethoprim.
AID57582In vitro inhibition of E. Coli dihydrofolate reductase.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted-benzyl)-2,4-diaminopyrimidines.
AID57574Activity against dihydrofolate reductase of Escherichia coli strain MB 14281992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors.
AID65357Inhibition of growth of methotrexate-sensitive (MB1417) strain of Escherichia coli cells.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.
AID1146765Inhibition of Escherichia coli dihydrofolate reductase1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships of antimalarial and dihydrofolate reductase inhibition by quinazolines and 5-substituted benzyl-2,4-diaminopyrimidines.
AID1404651Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus COL at 5 ug after 18 to 20 hrs by CLSI disk diffusion assay2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics.
AID56796Inhibition of dihydrofolate reductase from bovine liver1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted-benzyl)-2,4-diaminopyrimidines.
AID99656Inhibitory activity against murine tumor cells (L5178Y/S)1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Inhibition by 5-(substituted-benzyl)-2,4-diaminopyrimidines of murine tumor (L5178Y) cell cultures sensitive to and resistant to methotrexate. Further evidence for the sensitivity of resistant cells to hydrophobic drugs.
AID57583Inhibition of dihydrofolate reductase (DHFR) from Escherichia coli.1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID27589Partition coefficient (logD) (0.01 N NaOH)1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
On the structure selectivity problem in drug design. A comparative study of benzylpyrimidine inhibition of vertebrate and bacterial dihydrofolate reductase via molecular graphics and quantitative structure-activity relationships.
AID58101Inhibitory activity against dihydrofolate reductase (DHFR) of Neisseria gonorrhoea1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 7. Analysis of the effect of 3,5-dialkyl substituent size and shape on binding to four different dihydrofolate reductase enzymes.
AID203184In vitro antibacterial activity against Shigella flexneri (CN6007)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID64568In vitro antibacterial activity against Escherichia coli (CN314)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID56792Inhibition of bovine liver dehydrofolate reductase.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted-benzyl)-2,4-diaminopyrimidines.
AID99653Inhibitory activity against murine tumor cells (L5178Y/R)1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Inhibition by 5-(substituted-benzyl)-2,4-diaminopyrimidines of murine tumor (L5178Y) cell cultures sensitive to and resistant to methotrexate. Further evidence for the sensitivity of resistant cells to hydrophobic drugs.
AID58256Inhibitory activity against double mutant dihydrofolate reductase (C59R+S108N DHFR)2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
AID65359Inhibition of growth of methotrexate-resistant (MB1428) strain of Escherichia coli cells.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.
AID163241In vitro antibacterial activity against Proteus vulgaris (CN3296)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID96248In vitro antibacterial activity against Klebsiella pneumoniae (CN 3632)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID1124510Inhibition of bovine liver dihydrofolate reductase using dihydrofolic acid as substrate1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Quantitative structure-activity relationship of 5-(X-benzyl)-2,4-diaminopyrimidines inhibiting bovine liver dihydrofolate reductase.
AID57785Inhibitory activity against dihydrofolate reductase (DHFR) enzyme from rat liver1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID58112Inhibitory activity against dihydrofolate reductase (DHFR) enzyme from Plasmodium berghei1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID58106Inhibitory activity against dihydrofolate reductase (DHFR) enzyme from Neisseria gonorrhoeae1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID57779Inhibitory activity against Lactobacillus casei dihydrofolate reductase1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
On the structure selectivity problem in drug design. A comparative study of benzylpyrimidine inhibition of vertebrate and bacterial dihydrofolate reductase via molecular graphics and quantitative structure-activity relationships.
AID56794Inhibition of bovine liver dihydrofolate reductase.1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Theory and application of molecular potential energy fields in molecular shape analysis: a quantitative structure--activity relationship study of 2,4-diamino-5-benzylpyrimidines as dihydrofolate reductase inhibitors.
AID56784Inhibitory activity against bovine liver dihydrofolate reductase at pH 7.2.1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
A comparison of the inhibitory action of 5-(substituted-benzyl)-2,4-diaminopyrimidines on dihydrofolate reductase from chicken liver with that from bovine liver.
AID57584Apparent inhibitory (log 1/Ki) activity against Escherichia coli dihydrofolate reductase1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Quantitative structure-activity relationships for the inhibition of Escherichia coli dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines.
AID206280In vitro antibacterial activity against Staphylococcus aureus (CN491)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID57106Inhibitory activity against dihydrofolate reductase (DHFR) enzyme from Escherichia coli1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID56473Inhibitory activity against dihydrofolate reductase (DHFR) enzyme from chicken liver1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 8. The 3,4,5-triethyl isostere of trimethoprim. A study of specificity.
AID58278Inhibitory activity against quadruple mutant dihydrofolate reductase (N51I C59R S108N I164L DHFR), relative to trimethoprim2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum.
AID57925Inhibitory activity against dihydrofolate reductase (DHFR) from Lactobacillus casei (expressed as log 1/Kiapp)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Comparison of the inhibition of Escherichia coli and Lactobacillus casei dihydrofolate reductase by 2,4-diamino-5-(substituted-benzyl)pyrimidines: quantitative structure-activity relationships, X-ray crystallography, and computer graphics in structure-act
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (40.38)18.7374
1990's8 (15.38)18.2507
2000's3 (5.77)29.6817
2010's13 (25.00)24.3611
2020's7 (13.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.61 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index43.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]